Mipomersen sodium: First global approval

Drugs

Volumn 73, Issue 5, 2013, Pages 487-493

  Hair, Philip ^a   Cameron, Fiona ^a   McKeage, Kate ^b  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; MIPOMERSEN; PLACEBO; SIMVASTATIN;

ARTICLE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; HYPERCHOLESTEROLEMIA; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES;

EID: 84879443683     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0042-2     Document Type: Article

References (36)

1. Gelsinger C, Steinhagen-Thiessen E, Kassner U. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs. 2012;72(11):1445-55.
2. Ricotta DN, Frishman W. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev. 2012;20(2):90-5.
3. Visser ME, Witztum JL, Stroes ESG, et al. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012;33(12):1451-8.
4. Parhofer KG. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid. 2012;7:29-38.
5. Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl.):S18-29.
6. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia. BMJ. 2008;. doi: 10.1136/bmj.a2423.
7. Corporation Genzyme. Kynamro™ (mipomersen sodium): US prescribing information. Cambridge: Genzyme Corporation; 2013.
8. Genzyme, Isis Pharmaceuticals Inc. FDA advisory committee recommends Kynamro™ for homozygous familial hypercholesterolemia [media release]. Accessed 18 Oct 2012. http://www.isispharm.com.
9. US FDA. FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder [media release]. Accessed 29 Jan 2013. http://www.fda.govt.
10. Genzyme, Isis Pharmaceutcials Inc. Genzyme and Isis announce submission of European marketing authorization application for mipomersen (Kynamro™) [media release]. Accessed 28 Jul 2011. http://www.genzyme.com.
11. European Medicines Agency. Refusal of the marketing authorisation for Kynamro (mipomersen) [media release]. Accessed 13 Dec 2012.
12. Genzyme, Isis Pharmaceutcials Inc. Genzyme and Isis provide update on CHMP opinion on Kynamro™ (mipomersen) [media release]. Accessed 14 Dec 2012. http://www.genzyme.com.
13. Isis Pharmaceuticals Inc. Isis reports reduction of apoB-100 levels in a murine model resulting in up to 92% reduction of atherosclerosis [media release]. Accessed 18 Apr 2008. http://www.isispharm.com.
14. Isis Pharmaceuticals Inc. ISIS 301012 reduces atherosclerotic plaques in animal models [media release]. Accessed 27 Apr 2006. http://www.isispharm.com.
15. Isis Pharmaceuticals I. Isis Pharmaceuticals' oral formulation of ISIS 301012 reduces cholesterol in humans [media release]. Accessed 7 Feb 2006. http://www.isispharm.com.
16. Genzyme Corporation, Isis Pharmaceuticals Inc. Genzyme and Isis complete licensing of mipomersen [media release]. Accessed 24 Jun 2008. http://www.genzyme.com.
17. Genzyme Corporation, Isis Pharmaceuticals Inc. Genzyme and Isis announce Hart-Scott-Rodino approval of collaboration [media release]. Accessed 1 Feb 2008. http://www.genzyme.com.
18. Genzyme Corporation, Isis Pharmaceuticals Inc. Genzyme and Isis announce strategic alliance including exclusive worldwide license of mipomersen [media release]. Accessed 7 Jan 2008. http://www.genzyme.com.
19. Isis Pharmaceuticals Inc. Isis acquires Symphony GenIsis [media release]. Accessed 27 Sep 2007. http://www.isispharm.com.
20. Isis Pharmaceuticals Inc. Isis Pharmaceuticals and Symphony GenIsis enter into $75 million product development collaboration [media release]. Accessed 7 Apr 2006. http://www.isispharm.com.
21. Isis Pharmaceuticals Inc. ISIS 301012 produces significant and durable reductions in cholesterol in humans [media release]. Accessed 9 Jun 2005. http://www.isispharm.com.
22. Bradley J, Crooke R, Graham M. Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of ApoB in healthy volunteers [abstract no. 727]. Circulation. 2005;112(Suppl.):133-4.
23. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008;118(7):743-53.
24. Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet. 2009;48(1):39-50.
25. McGowan MP, Tardif J-C, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE. 2012;. doi: 10.1371/journal.pone.0049006.
26. Cromwell WC, Thomas GS, Boltje I, et al. Safety and efficacy of mipomersen administered as addon therapy in patients with hypercholesterolemia and high cardiovascular risk+. Annual Scientific Sessions of the National Lipid Association, 31 May-3 Jun 2012; Scottsdale.
27. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulations. 2012;126(19):2283-92.
28. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006.
29. Parhofer KG, Vogt A. Mipomersen, an APOB synthesis inhibitor, evaluation of potential to reduce necessity for lipid-apheresis in patients with heterozygous FH and CAD [abstract]. 79th European Athersclerosis Society Congress, 26-29 Jun 2011. Gothenburg; 2011.
30. Duell PB, Santos RD, East C, et al. Long-term safety and efficacy of mipomersen in patients with familial hypercholesterolemia uncontrolled by maximally tolerated lipid lowering therapy. Annual Scientific Sessions of the National Lipid Association, 31 May-3 Jun 2012. Scottsdale.
31. Akdim F, Stroes ESG, Sijbrands EJG, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55(15):1611-8.
32. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105(10):1413-9.
33. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32(21):2650-9.
34. Kastelein JJP, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114(16):1729-35.
35. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33(9):1142-9.
36. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51(5):1057-62.